Pharmaceutical drugs can be traced as far back as 750 A.D., but it is known that individuals have been “self-prescribing” themselves and using different forms of medications since 2000 B.C. After World War II in 1942, the manufacturing of pharmaceutical drugs became mechanized. There were now drug stores and pharmacy all around the world. This means, every country has their own methods and techniques when it comes to pharmaceutical drugs. The United States is a country that does not regulate the price of pharmaceutical products candidly, unlike many other countries, which sounds like a disadvantage but it is actually an advantage when understood. The United States has a generic pharmaceutical market, which is cost effective and creates completion within drug manufacturers. The creator of a publically valuable patented drug company may charge extreme prices in the United States market, and the following profit incentivizes invention that benefits from consumers. Succeeding competition between alternative treatments, even those on patent, can lower these prices over a period of time. Generic entrance after patient termination can lower prices down even more. This form of price restraint, produced by market dynamisms, prizes the qualities and values that customers want. For example, if a specific drug is distinguished from its competitors in a suitable way, it will be able to be sold for a greater price.
Prices that imitate value produce exactly the incentives society yearns for innovation. If the powers of competition are continuously strong, then the way for a pharmaceutical company to earn high profits is to formulate a valuable treatment. If competitive forces decline, then high prices for drugs may not reveal value but instead an absence of market disciple, which occasionally are impaired by regulations that empower or preserve high prices. When manufactures can receive high revenue by pushing for regulations that reduce competition, or by emerging mechanism to dodge competition, the system no long incentivizes the create of valued drugs. Rather, it incentivizes corporations to trace regulatory roles where they are protected from competition on the distinctions with their competition. The United States method accomplishes great things when competitive powers are strong, as this harvests low prices for customers as well as improvement that they value.
How Prices of Drugs are Determined:
Prices that imitate worth produce precisely what the incentives society desires for innovation. If the rivalries of competition are constantly tough, then the best system for a pharmaceutical company to gross high profits is to formulate a valuable treatment. If competitive powers decline, then high prices for drugs may not imitate worth but in its place a nonexistence of market chastisement, sometime intensified by regulations that empowers or keeps those high prices going. When drug companies can earn excessive profits by petitioning for regulations that will cause competition to weaken, or by emerging mechanism to dodge competitors, there is not longer an appreciation of valuable drugs. Relatively, it stimulates companies to pinpoint and crack down on controlling their drugs where they can be safe from competitors. The United States has a arrangement that achieves and accomplishes more when competitive powers are solid, as this revenues low costs for customers as well as allows for improvement. Because of drug companies estimating power and their capability to upsurge prices without instruction, the concern about slow-moving demand of drugs is not even on the list of priorities or concerns relative to pricing. Pharmaceutical drug companies worry themselves with an assortment of issues when it comes to pricing drugs. The distinctiveness of the drug must be well thought out. For example, how many various drugs have been previously accessible that treat the same illness or disorder.
If the drug market is forcefully flooded with drugs to all treat the same illness or disorder, new drugs for the exact or similar illness or disorder will most likely expected be put on the market for a lower price. Competition is an additional reason that affects the pricing of drugs. Drug companies have to contemplate the reputation and accomplishments of the drug’s competition, and use that to regulate if new drugs have anything to offer over competing drugs that will draw people to pick the new drug instead. When a drug offers more welfares than other drugs of its type, it causes it to be placed at a higher price. Drug companies must also contemplate whether new drugs have the possibility to adjust or improve the existing practice of medicine used to treat the illnesses the drugs aim to challenge.
These drug corporations need to always contemplate whether their drugs can divert the need for many surgeries, medical treatments or the requirement of other procedures. Drugs that are able to reduce on high-priced surgeries, hospital bills and co-pays are frequently priced higher because they are saving customers money in the long run by not having to pay for the surgeries and procedures. Either way they are finding a way to take money out of the consumer’s pockets, by either paying for the drug or procedure. Drug companies also release higher prices to drugs that can prolong or even protect lives and save individuals from life threatening diseases. Even with all of that, the underlying objective for pharmaceutical drug companies when determining the price of drugs is actually very unpretentious. The major target is to place a price on drugs that will produce the most income. This regularly means confronting competition, which helps to lower the prices of drugs. Nevertheless, drug companies have secured the method of pricing drugs too low with the capability to ratify price upsurges at constant rate.
This also brings up the topic of how drugs can be priced the wrong way. Determining a price for a drug inaccurately is one of the major errors a drug company can make. Setting a price for a drug that is too high or too low creates a huge impact on how successful that drug can be. For example, when drugs are placed at a high price, companies may not be eager to compensate for it or doctors may be reluctant to prescribe the medications. They may suppose that the medication is not valued enough to be held at such a high price. In their opinion, if a medication does not offer enough benefits over other medications of its type that it is not worth the price. That also brings up the fact that , if a medication is priced at low amount, doctors may determine that it is not as effective or powerful than the more expensive medication that is used for the same disease or illness.
The study and progression neighboring each drug is another overwhelmingly imperative problem in regard to setting a price for pharmaceutical drugs. The time and money that is spent on the study and improvement for every drug and medication that created is all taken into consideration when the drug has to be priced. This is why sometimes a drug may be priced a higher rate because the cost to produce and develop it might be high as well.
Drug Companies Raise their Prices:
Rather than dropping prices, the way Medicare process medications, it causes drug prices to rise. Medicare recompenses doctors for prescribing high price medications. It is not legal for Medicare to negotiate with drug companies but instead private insurers do the negotiating. The government tends to have their hands tied behind their backs because they are obligated to keep purchasing these drugs even at the outrageous prices with exclusion. Their major consumers are obligated to purchase their drugs and are forbidden from trying to negotiate or get a better deal on high priced medications. When these high priced medications are sold they are encouraging the modernization, for these drugs companies to keep going and keep raising their prices on a continuous basis.
For example there is a pharmaceutical company named Pfizer that has elevated their prices of 100 drugs by 20 cent during this year. This number continues to rise . On June 1st, Pfizer raised the prices of 91 of their medications from anywhere from 5 to 13 cents. Their most profitable drugs like Lyrica, which is used for nerve pain and Viagra that is used for erectile dysfunction treatment were included in the 91 medications. June was the second time in 2017 that Pfizer has raised the price of their pharmaceutical drugs. The first time was in January of this year where they raised prices of medications by 20 cents and even more for some of their drugs.
To go into detail with those drugs, a tablet of Viagra was priced at $57.94 and that is only for one tablet, after the two upsurges the price of one tablet shot up to $73.85, which leads to the over-all increase of 27.5% per cent. Pfizer’s choice to raise the price of their medications is a sort of domino effect; they are reacting off what other drug manufacturers are doing. Like in 2015, Martin Shkreli decided to increase the price of a medication that is used for AIDS from $13.50 per tablet to $750 just for one tablet. That is a huge increase, and just by looking at that number, of course most people cannot afford that.
One of the promises, President Trump has promised to make is to clamp down on pharmaceutical companies who are continuously raising the prices of the drugs and even said that the pharmaceutical industry is “getting away with murder”. When he says that, I believe he is saying that are getting away with murder because people are not able to afford the medication that is medically necessary to keep them alive. The higher these prices get the more people will not be able to afford them which will eventually lead to more lives being taken away due to medical illness and diseases. Even though the magnitude of Pfizer’s price upsurges show similar details to the things Martin Shkreli has done, criticizers debate that yearly double-digit growths on a great amount of medications will end up costing the United States healthcare system more in the long run. Even the chief executive of Rx Savings Solutions said “The net effect of price increases on this many products is far more costly and impactful for the American health economy than anything Shkreli ever did by raising one drug by 5,000 per cent". Rx Savings Solution helps patients save money on high costing medications and acts like a discount card.
Possible Economic Solutions:
There are many solutions that come to mind the topic of high prescription drug prices are brought up. Many suggest assistance programs that help pay a chunk of the prescription costs , using generic drugs instead of name brands and looking for social security Medicare programs that you qualify for in order to I think the best possible way to help lower the prices of pharmaceutical drugs to be affordable and economical to consumers is to find a universal paying system. There are many different theories that people think that can work if done right and is thought out before executed. For example, one solution is that the federal government should negotiate with drug companies by using Medicare as their defense mechanism. They are using Medicare as a point in the solution because Medicare is responsible for responsible for letting hospitals and doctors know what they want them to pay for services but it is not yet legal for Medicare to be able to negotiate with drug companies about the costs of drug prices.
Some self-governing approximations propose that when drug prices are negotiated it could possibly save the government a potential $15 billion dollars or more every year. Unfortunately, even negotiations will not be able to save the constant upsurge or drug prices. Some conditions only have few medications that can actually be effective in treating that illness. That means that there will most likely be higher prices set for that type of medication because there is not a lot of manufacturers for it. That also emphasizes that there is not a lot of completion for those types of medications. Another thing is that even if Medicare tries to negotiate these drug prices, there are so many people that are insured through private healthcare insurers. That would mean that ever individual or family with private insurance would get nothing out of it and honestly it might just bring up the price of medications on the private insurance side.